|1.||Heinrich, Michael C: 3 articles (08/2009 - 11/2004)|
|2.||Druker, Brian J: 2 articles (12/2006 - 11/2004)|
|3.||Chen, Jun-Jiang: 1 article (06/2013)|
|4.||Dai, Chun-Ling: 1 article (06/2013)|
|5.||Chen, Zhe-Sheng: 1 article (06/2013)|
|6.||Kathawala, Rishil J: 1 article (06/2013)|
|7.||Deng, Wen: 1 article (06/2013)|
|8.||Fu, Li-Wu: 1 article (06/2013)|
|9.||Chen, Hai-Fan: 1 article (06/2013)|
|10.||Sun, Yue-Li: 1 article (06/2013)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/01/2002 - "CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)."
12/01/2006 - "Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS). "
12/01/2006 - "Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics."
10/01/2003 - "Gemtuzumab ozogamicin (Mylotarg) for the treatment of patients with CD33-positive acute myeloid leukemia, selective FLT3 inhibitors currently in advanced development (e.g., SU11248, PKC412, CT53518 and CEP-710) and other targeted compounds (e.g., farnesyl transferase inhibitors, BCL-2 inhibitors and interleukin-2) may present initial opportunities to achieve improved outcomes."
06/01/2013 - "Thus, we conclude that the FLT3 inhibitor tandutinib can reverse MRP7-mediated MDR through inhibition of the drug efflux function and may have potential to be used clinically in combination therapy for cancer patients."
03/01/2012 - "Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. "
01/01/2008 - "Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications."
05/01/2013 - "Together, these data suggest that tandutinib is a novel potent therapeutic agent that can target the Akt/mTOR/p70S6K signaling pathway to inhibit tumor growth and angiogenesis."
03/01/2012 - "To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. "
11/01/2004 - "In these assays, we show that MLN518 has mild toxicity toward normal hematopoiesis at concentrations that are effective in treating FLT3 ITD-positive leukemia in mice. "
01/18/2011 - "Tandutinib (MLN 518, Millennium Pharmaceuticals, Cambridge, MA) is an orally active multitargeted tyrosine kinase inhibitor that is currently under evaluation for the treatment of glioblastoma and has been used in the treatment of leukemia. "
11/01/2004 - "MLN518 (formerly CT53518) is a small molecule inhibitor of the FLT3, KIT, and platelet-derived growth-factor receptor (PDGFR) tyrosine kinases with significant activity in murine models of FLT3 ITD-positive leukemia. "
|4.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2008 - "Phase II clinical trials for tandutinib are ongoing in patients with AML or renal cell carcinoma."
02/01/2012 - "In this trial, 10 patients with metastatic renal cell carcinoma refractory to previous therapy with sunitinib or sorafenib (median age 61 years, 80% performance status 0, 60% intermediate MSKCC risk classification) received tandutinib 500 mg bid daily with RECIST-defined response as the primary endpoint and progression-free survival (PFS) and overall survival (OS) as secondary endpoints. "
02/01/2012 - "Tandutinib had no clinical activity and due to the excessive toxicity should not be developed further in patients with sunitinib or sorafenib-refractory metastatic renal cell carcinoma."
02/01/2012 - "A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma."
01/18/2011 - "This study provides Class III evidence that tandutinib 500 mg twice daily induces reversible muscle weakness and electrophysiologic changes consistent with neuromuscular junction dysfunction."
12/01/2006 - "Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily. "
|2.||70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)
|6.||gemtuzumab (gemtuzumab ozogamicin)
|7.||4- (6- methoxy- 7- (3- piperidin- 1- ylpropoxy)quinazolin- 4- yl)piperazine- 1- carboxylic acid (4-isopropoxyphenyl)amide
|10.||sorafenib (BAY 43-9006)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Highly Active Antiretroviral Therapy (HAART)